Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 13,741	$ 10,596
Accounts receivable	50	157
Prepaid expenses and other current assets	1,071	533
Total current assets	14,862	11,286
Property and equipment, net	327	416
TOTAL ASSETS	15,189	11,702
Current liabilities:
Accounts payable	957	3,169
Accrued expenses	1,208	1,937
Senior secured convertible debt, net		8,074
Total current liabilities	2,165	13,180
Long-term debt	1,134	1,134
TOTAL LIABILITIES	3,299	14,314
Commitments and contingencies (Note 7)
Stockholders’ equity (deficit):
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of September 30, 2021, and December 31, 2020; 30,801,962 and 22,388,027 shares issued as of September 30, 2021 and December 31, 2020, respectively; 30,801,110 and 22,387,175 shares outstanding as of September 30, 2021 and December 31, 2020, respectively	3	3
Additional paid-in capital	307,128	250,914
Treasury stock, at cost; 852 shares of common stock as of September 30, 2021 and December 31, 2020, respectively	(11)	(11)
Accumulated deficit	(295,230)	(277,481)
Total Vaccinex, Inc. stockholders’ equity (deficit)	11,890	(26,575)
Noncontrolling interests		23,963
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	11,890	(2,612)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 15,189	$ 11,702